Guanxinning for Residual Inflammation of Stable Coronary Artery Disease: A Pilot Randomized Controlled Trial
Tielong Chen, Jianwu Zheng, Cheng Bao, Yu Wang, Shiwang Wang, Lu Liang, Li Zhang, Hui Zhang, Chaoxia Ji, Jian Wang, Xudong Zhang, Guangli Zhu, Houyong Zhu · 2024
Read Guanxinning for Residual Inflammation of Stable Coronary Artery Disease: A Pilot Randomized Controlled Trial by Tielong Chen, Jianwu Zheng, Cheng Bao, Yu Wang, Shiwang Wang, Lu Liang, Li Zhang, Hui Zhang, Chaoxia Ji, Jian Wang, Xudong Zhang, Guangli Zhu, Houyong Zhu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11539777.txt.
Description
BackgroundDespite statins and other medications central to atherosclerotic cardiovascular disease (ASCVD) secondary prevention, stable coronary artery disease (SCAD) patients remain at significant cardiovascular risk, partly due to residual inflammation risk (RIR). This study aims to assess if adding Guanxinning to standard ASCVD therapy further mitigates RIR in SCAD patients.
Catalog record
| CREATOR | Tielong Chen, Jianwu Zheng, Cheng Bao, Yu Wang, Shiwang Wang, Lu Liang, Li Zhang, Hui Zhang, Chaoxia Ji, Jian Wang, Xudong Zhang, Guangli Zhu, Houyong Zhu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |